Wealthquest Corp Makes New $347,000 Investment in Krystal Biotech, Inc. (NASDAQ:KRYS)

Wealthquest Corp acquired a new position in Krystal Biotech, Inc. (NASDAQ:KRYS - Free Report) during the first quarter, according to the company in its most recent filing with the SEC. The fund acquired 1,923 shares of the company's stock, valued at approximately $347,000.

A number of other institutional investors have also recently added to or reduced their stakes in the company. FMR LLC lifted its holdings in Krystal Biotech by 0.5% in the 4th quarter. FMR LLC now owns 4,314,014 shares of the company's stock worth $675,833,000 after buying an additional 21,133 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Krystal Biotech by 1.0% in the 4th quarter. Vanguard Group Inc. now owns 2,878,451 shares of the company's stock worth $450,938,000 after buying an additional 28,707 shares in the last quarter. Avoro Capital Advisors LLC raised its position in shares of Krystal Biotech by 0.3% in the 4th quarter. Avoro Capital Advisors LLC now owns 2,628,822 shares of the company's stock valued at $411,831,000 after purchasing an additional 6,600 shares in the last quarter. Hood River Capital Management LLC boosted its stake in shares of Krystal Biotech by 2.1% during the 4th quarter. Hood River Capital Management LLC now owns 512,726 shares of the company's stock valued at $80,324,000 after buying an additional 10,622 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD boosted its stake in shares of Krystal Biotech by 16.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 509,459 shares of the company's stock valued at $79,812,000 after buying an additional 71,200 shares during the last quarter. Institutional investors and hedge funds own 86.29% of the company's stock.

Krystal Biotech Stock Down 2.6%

NASDAQ KRYS traded down $3.70 during trading hours on Friday, hitting $138.88. The company had a trading volume of 418,422 shares, compared to its average volume of 289,301. Krystal Biotech, Inc. has a fifty-two week low of $122.80 and a fifty-two week high of $219.34. The business has a fifty day simple moving average of $140.66 and a 200-day simple moving average of $157.85. The firm has a market cap of $4.01 billion, a P/E ratio of 33.38 and a beta of 0.65.

Krystal Biotech (NASDAQ:KRYS - Get Free Report) last issued its earnings results on Tuesday, May 6th. The company reported $1.20 earnings per share for the quarter, missing the consensus estimate of $1.38 by ($0.18). Krystal Biotech had a return on equity of 14.64% and a net margin of 37.17%. The company had revenue of $88.18 million during the quarter, compared to analyst estimates of $98.66 million. Equities analysts forecast that Krystal Biotech, Inc. will post 6.14 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

KRYS has been the subject of several research analyst reports. Guggenheim reduced their target price on Krystal Biotech from $195.00 to $189.00 and set a "buy" rating for the company in a research note on Wednesday, May 7th. HC Wainwright reiterated a "buy" rating and set a $240.00 target price on shares of Krystal Biotech in a research note on Tuesday. Chardan Capital reiterated a "buy" rating and set a $219.00 target price on shares of Krystal Biotech in a research note on Wednesday, May 7th. Jefferies Financial Group started coverage on Krystal Biotech in a research note on Wednesday, March 5th. They set a "buy" rating and a $245.00 target price for the company. Finally, Citigroup dropped their price target on Krystal Biotech from $215.00 to $155.00 and set a "neutral" rating on the stock in a research report on Friday, May 16th. One equities research analyst has rated the stock with a hold rating, seven have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of "Buy" and a consensus price target of $211.13.

About Krystal Biotech

Krystal Biotech, Inc, a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB).